The FDA now publishes cosmetic adverse event reports through a public dashboard, updated daily. Anyone — a competitor, a journalist, a customer mid-purchase — can filter reports by product type, date and severity and see what has been submitted about a category.
For scalp care, that changes the accountability picture in a concrete way. Complaints about irritation from an anti-dandruff product used to sit in a company’s internal complaints log. A portion of them are now visible to the public as they arrive.
What’s in it, and what isn’t
The dashboard aggregates reports submitted under the Modernization of Cosmetics Regulation Act, drawing from three sources: responsible parties who are legally required to report, healthcare providers, and consumers submitting voluntarily.
Several things follow from that structure, and they matter more than the headline feature:
- A report is an allegation, not a finding. The FDA is explicit that inclusion does not establish that the product caused the event, and nothing in the submission process verifies causation.
- Volume tracks attention as much as it tracks risk. A product with large distribution, or one that recently went viral, will generate more reports than a small-batch equivalent with identical safety behaviour.
- Consumer submissions describe symptoms, not mechanisms. “Scalp irritation” in a report may be contact dermatitis, a reaction to fragrance rather than the active, or an unrelated flare.
None of that makes the dashboard less useful. It makes it a signal-detection tool rather than a verdict, which is exactly what regulators say it is.
The classification wrinkle for scalp products
Here’s the detail that catches brands out. In the United States, a dandruff shampoo built on zinc pyrithione, selenium sulfide or ketoconazole is not a straightforward cosmetic — those actives are regulated on the drug side, which makes the finished product a drug-cosmetic combination.
That splits the compliance picture. The cosmetic obligations under MoCRA apply, and so does the drug-side regime, with its own labelling requirements and its own reporting expectations. A brand that maps its entire scalp portfolio onto the cosmetic framework alone has misread its own products.
The practical implication for anyone launching into the US market: settle the classification question before formulation, not after. Whether the anti-dandruff active is a monograph ingredient at a monograph concentration determines the label format, the claim language, the testing burden and the reporting path. Reformulating to change that answer after the fact is expensive.
The reporting clock
Responsible parties must submit serious adverse event reports within 15 business days of receiving them, with a window for follow-up submissions if new information surfaces within a year. MoCRA also gave the FDA mandatory recall authority, which it did not previously hold for cosmetics.
Fifteen business days is not long if complaints arrive through scattered channels. A brand whose customer service inbox, retailer feedback, marketplace reviews and social mentions are handled by four different people has no reliable way to know when the clock started. Building a single intake point is unglamorous operational work and it’s the thing that actually determines whether a company meets the deadline.
The same discipline pays off internally. A complaints log that codes reports by active, batch and symptom lets a formulator see a pattern — a fragrance change correlating with a rise in irritation reports, say — months before it would show up as a regulatory problem.
Reading the data without misreading it
The most common complaint types in this category are predictable: scalp irritation and itching, dryness, and reports of hair thinning or shedding. The third one deserves particular care. Seborrheic dermatitis itself is associated with shedding, so a consumer who starts a treatment shampoo during a flare and then notices hair in the drain has a plausible reason to attribute it to the product and no way to separate the two. Reports of this kind will keep appearing regardless of formulation quality.
What this does to the marketing
Safety language used to be a compliance formality — copy nobody read, approved by legal, printed small. A public database changes that, because a curious buyer can now check. That’s a narrow shift with wide consequences.
The most defensible position is specificity. Naming the active and its concentration, describing what it does and who it suits, and saying plainly what the tolerance profile looks like reads as more credible than a general assurance of gentleness. Vague efficacy language of the kind that draws regulatory attention on labelling and advertising in other categories is the same language that ages badly here.
There is also a reformulation trend worth reading correctly. Movement toward lower-irritation systems, gentler surfactants and botanical adjuncts like tea tree or aloe is real, and it is partly a response to consumer preference rather than to evidence of harm from the established actives. A brand should be honest with itself about which motivation applies, because a formula that swaps out a proven antifungal for a gentler alternative may also swap out the efficacy that made customers buy it — which is the same trap that catches brands reformulating a damage-repair shampoo toward a cleaner ingredient list.
Brands that were already straightforward about their formulas gain from this transparency. The ones that weren’t are now carrying a reputational exposure that didn’t exist eighteen months ago.
“A public adverse-event dashboard changes the marketing conversation for hair care brands in a pretty concrete way — it means safety claims aren’t just a compliance checkbox anymore, they’re something a curious customer could actually go verify. In client conversations, we’re encouraging brands to get ahead of that shift by being more specific and less promotional in how they describe active ingredients like ketoconazole or zinc pyrithione, rather than leaning on vague clinically-proven language. Our honest read is that this kind of transparency tool tends to reward brands that were already being straightforward with customers, and creates real reputational risk for the ones that were cutting corners on how they described their formulas.” — Hyejin Cho, Digital Marketing Specialist, Marketing and Communication Team at SPSCOS